Revenue
2022
2023
2024
2025
Anebulo Pharmaceuticals, Inc. (ANEB)
Price$0.3586Cached quote
Net income
2021
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $4.3M | $3.5M | $5.6M | $3.0M | $2.3M |
| Operating expenses | $9.2M | $8.3M | $11.8M | $6.8M | $3.6M |
| Operating income | −$9.2M | −$8.3M | −$11.8M | −$6.8M | −$3.6M |
| EBITDA | −$8.1M | −$8.1M | −$11.7M | −$6.8M | — |
| Net income | −$8.5M | −$8.2M | −$11.7M | −$6.8M | −$30.3M |
| Basic EPSper basic share | -$0.25 | -$0.32 | -$0.47 | $0.29 | -$2.83 |
| Diluted EPSper diluted share | -$0.25 | -$0.32 | -$0.47 | $0.29 | -$2.83 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
English Aron R. / 22NW Fund, LP | 20.12M |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 23, 2024Form 4 | English Aron R. +1Director,TenPercentOwner | BuyCommon Stock · indirect | 10.10M | $0.99 | $10.00M | 15.47M |